Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection

J Hepatol. 2019 May;70(5):1019-1023. doi: 10.1016/j.jhep.2019.01.031. Epub 2019 Mar 8.
No abstract available

Keywords: G/P; HCV; RAS; Resistance; Retreatment.

Publication types

  • Clinical Trial, Phase III
  • Letter
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aminoisobutyric Acids
  • Benzimidazoles / administration & dosage*
  • Cyclopropanes
  • Drug Therapy, Combination
  • Female
  • Hepatitis C / drug therapy*
  • Hepatitis C / virology
  • Humans
  • Lactams, Macrocyclic
  • Leucine / analogs & derivatives
  • Male
  • Middle Aged
  • Proline / analogs & derivatives
  • Pyrrolidines
  • Quinoxalines / administration & dosage*
  • Retreatment
  • Sofosbuvir / administration & dosage
  • Sulfonamides / administration & dosage*
  • Sustained Virologic Response
  • Treatment Failure

Substances

  • Aminoisobutyric Acids
  • Benzimidazoles
  • Cyclopropanes
  • Lactams, Macrocyclic
  • Pyrrolidines
  • Quinoxalines
  • Sulfonamides
  • pibrentasvir
  • Proline
  • Leucine
  • glecaprevir
  • Sofosbuvir

Associated data

  • ClinicalTrials.gov/NCT02939989